Rett syndrome

Reading File

Finding Sources

Searching PubMed

"Rett syndrome"[MeSH Terms] AND MECP2

Searching Images

Rett syndrome hand wringing stereotyped movements clinical features

Reading File

Loading Image

I now have comprehensive information from multiple authoritative textbooks. Let me compose the full answer.

Rett Syndrome

OMIM #312750

Rett syndrome is an X-linked dominant neurodevelopmental disorder caused by loss-of-function variants in the MECP2 gene. First described by Austrian physician Andreas Rett in 1966 after he noticed a distinctive hand-wringing pattern, it is one of the most common monogenic causes of cognitive impairment, with a prevalence of 1 in 10,000 female births - more common than phenylketonuria.

Holly, a young girl with Rett syndrome, demonstrating the characteristic hand-wringing posture - an easily recognizable clinical clue to the diagnosis.

Holly demonstrating hand-wringing - the hallmark clinical sign of Rett syndrome. (Photo courtesy of International Rett Syndrome Foundation, from Thompson & Thompson Genetics and Genomics in Medicine, 9th ed.)

Genetics and Molecular Pathogenesis

The MECP2 Gene

Located at chromosome Xq28
Encodes methyl-CpG binding protein 2 (MeCP2), a nuclear protein expressed in all tissues, particularly abundant in the brain
MeCP2 contains three key functional domains:
- MBD (methyl-CpG binding domain) - binds methylated cytosine residues, with preference for CpG dinucleotides adjacent to A/T-rich motifs
- TRD (transcriptional repression domain) - interacts with histone deacetylases and transcription co-repressors
- CTD (C-terminal domain) - enables nucleosome binding and naked DNA binding
Pathogenic variants found in ~95-98% of classic Rett syndrome
Over 900 unique variants reported (nonsense, missense, frameshift, large deletions)
Eight common mutation hotspots account for the majority of cases
~99% of cases are sporadic (de novo mutations); at least 70% of de novo variants arise in the paternal germline

Molecular Mechanism

MeCP2 mediates transcriptional silencing and epigenetic regulation by binding methylated DNA and recruiting histone deacetylases. Loss of MeCP2 leads to:

Inappropriate activation of target genes
Reduced expression of key neuronal genes including BDNF (brain-derived neurotrophic factor)
Disrupted long-range chromatin remodeling and gene splicing

Brain pathology is notable: the brain is small with normal gross morphology and no neuronal loss - making it technically not a neurodegenerative disease. Neurons in the cortex and hippocampus are smaller, more densely packed, and have a simplified dendritic branching pattern, suggesting MeCP2 is important for establishing and maintaining neuronal interactions rather than neuronal proliferation.

Why Almost Exclusively Females?

Because females are mosaic due to random X-inactivation: approximately half their brain cells express the normal MECP2 allele. This mosaicism allows survival but produces the Rett phenotype. In contrast, hemizygous males (with a single X chromosome) typically die shortly after birth or in infancy from severe neonatal encephalopathy. Rare surviving males present with neonatal epileptic encephalopathy, microcephaly, abnormal tone, irregular breathing, and macroorchidism.

Clinical Features and Stages

Classic Rett syndrome follows a characteristic four-stage clinical progression:

Stage	Timing	Features
I - Early onset stagnation	6-18 months	Normal development until this point, then deceleration of head growth, developmental slowing
II - Rapid destructive	1-4 years	Rapid regression: loss of speech, loss of purposeful hand use, social withdrawal (autism-like), breathing irregularities, ataxia, onset of seizures
III - Plateau / pseudo-stationary	Preschool to early school age	Apparent stabilization; stereotypic hand movements persist; some social engagement may improve
IV - Late motor deterioration	Late childhood / teens	Progressive spasticity, rigidity, scoliosis, wheelchair-bound by teens; intellectual disability

Key Clinical Signs

Hand-wringing / "hand washing" stereotypies - the hallmark feature; distinguishable from the hand-flapping of autism
Microcephaly (acquired, from decelerated head growth)
Loss of purposeful hand use
Loss of language
Gait apraxia and ataxia
Epilepsy (common, often multiple seizure types)
Breathing irregularities when awake (hyperventilation, breath-holding, air swallowing)
Scoliosis / kyphosis
QTc prolongation on ECG - important due to risk of sudden death
Preservation of eye contact (notable contrast to autism)
Bruxism, sleep disturbances, inappropriate laughing/screaming, diminished pain response
Cold, small hands and feet (peripheral vasomotor abnormalities)

Prognosis

Many affected females survive into the sixth or seventh decade, though life span is shortened due to risk of unexplained sudden death (partly attributable to prolonged QTc). Males have earlier and more severe disease, with early death being common.

Diagnosis

Genetic Testing

DNA testing (single gene, gene panel, or genomic sequencing) detects pathogenic variants in:
- Up to 98% of classic/typical Rett syndrome
- ~86% of atypical/variant Rett syndrome

Clinical Diagnostic Criteria (Typical Rett)

All four must be present:

Partial or complete loss of acquired purposeful hand skills
Partial or complete loss of acquired language skills
Gait abnormalities (ataxia, apraxia)
Stereotypic hand movements (wringing, squeezing, clapping, mouthing)

Plus: normal prenatal/perinatal period with subsequent regression.

Supportive Features (not required, help diagnose atypical)

Breathing disturbances, bruxism, sleep disturbances, abnormal muscle tone, peripheral vasomotor abnormalities, scoliosis/kyphosis, growth retardation, and others.

ECG

An ECG should be obtained in all patients - QTc prolongation is common and has implications for both drug prescribing and sudden death risk.

Treatment and Management

There is currently no cure; management is supportive and symptomatic:

Problem	Management
Seizures	Anticonvulsants
Agitation	Serotonin reuptake inhibitors (SSRIs)
Rigidity	Carbidopa / levodopa
Sleep disturbances	Melatonin
Motor function	Physical and occupational therapy (individualized)
Scoliosis	Orthopedic management
QTc monitoring	Annual ECG

Trofinetide - FDA-Approved Treatment

Trofinetide (Daybue), a synthetic analogue of the neuropeptide IGF-1(1-3), was approved by the FDA in 2023. At 200 mg twice daily, it significantly improved functional status in clinical trials, though it does not restore normal function. It represents the first disease-specific pharmacologic treatment for Rett syndrome. - Goldman-Cecil Medicine, International Edition

Emerging Therapies

Gene therapy (preclinical trials showing promise)
BDNF / IGF-1 pathway modulation - overexpression of BDNF improved the mouse knockout phenotype; Phase II human trials of related compounds have been underway
X-reactivation strategies - exploiting favorable X-inactivation skewing to reactivate the normal silenced X chromosome in females

MECP2-Related Conditions Beyond Classic Rett

Pathogenic MECP2 variants cause a broader disease spectrum:

In girls: ranges from severe (never walk or speak, severe epilepsy) to mild (preserved motor and language function)
In boys: congenital encephalopathy, intellectual disability, or mild ID only
MECP2 duplication syndrome (MDS): duplications of MECP2 cause autistic features, hypotonia, epilepsy, gait abnormalities, and recurrent infections in males; female carriers are usually unaffected due to favorable X-inactivation

Inheritance Counseling

~99% sporadic (de novo)
Rare maternal transmission possible if mother has skewed X-inactivation (mildly or unaffected carrier)
If both parents test negative: recurrence risk is low but above background (due to germline mosaicism risk)
If mother is confirmed carrier: each child has 50% risk of inheriting the variant
Poor genotype-phenotype correlation limits prediction of severity in female fetuses

Sources: Goldman-Cecil Medicine (International Edition) | Thompson & Thompson Genetics and Genomics in Medicine (9th ed.) | Tietz Textbook of Laboratory Medicine (7th ed.) | Adams and Victor's Principles of Neurology (12th ed.) | Kandel's Principles of Neural Science (6th ed.)

Recent literature note: Reviews from 2024-2025 (PMID 40943197, PMID 41039661) highlight ongoing research into MECP2 molecular mechanisms, oxidative stress, hypoxia signaling, and emerging gene therapy approaches - consistent with textbook content but expanding on therapeutic targets.

This is a shared conversation. Sign in to Orris to start your own chat.